TMEM11

Across TCGA pan-cancer cohorts, TMEM11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM11 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM11 expression acts as an unfavorable survival marker.

CCRCC, LUAD, and LSCC are the cancer types where TMEM11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.554	0.846	.009	35	view →
LUAD	DFS	Quartile	III,IV	0.298	0.953	.010	10	view →
LSCC	DFS	Median	All	0.393	0.922	.001	9	view →
UCEC	OS	Quartile	II,III,IV	0.488	1.000	.031	4	view →
PDAC	DFS	Median	All	0.716	0.871	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM11–CCRCC (DFS)

Open the CCRCC breakdown →